Meanwhile, the BSE Sensex was up 9.33 points, or 0.06%, to 16,922.10.
On BSE, 11,620 shares were traded in the counter as against an average daily volume of 73,587 shares in the past one quarter.
The stock hit a high of Rs 173.65 and a low of Rs 170.50 so far during the day. The stock had hit a 52-week high of Rs 201.45 on 6 November 2009 and a 52-week low of Rs 67.50 on 13 March 2009.
The mid-cap stock had underperformed the market over the past one month till 16 December 2009, falling 10.15% as compared to the Sensex's 0.70% fall. It had also underperformed the market in the past one quarter, falling 0.31% as compared to the Sensex's return of 1.41%.
The company's equity capital is Rs 54.72 crore. Face value per share is Rs 5.
Ranitidine Hydrochloride is the generic version of GlaxoSmithKline's Zantac tablet. The drug is used for treating gastric ulcer.
In November 2009, the board of Wockhardt approved a preferential issue of up to 160 crore convertible/non-convertible redeemable preference shares of face value Rs 5 each.
Wockhardt reported a net loss of Rs 59.09 crore in Q3 September 2009 compared with a net profit of Rs 13.43 crore in Q3 September 2008. Net sales fell 2% to Rs 383.30 crore in Q3 September 2009 over Q3 September 2008.
Wockhardt specializes in the production of pharmaceuticals in both generic and prescription forms. The company has developed brands in a variety of segments, including anti-infective, pain & inflammation, cough, psychiatry, medical nutrition, vaccines, active pharmaceutical ingredients and biotechnology.
Promoters have pledged 5.78 crore shares representing 52.82% of the equity capital of the company. Total promoters shareholding in the company is 73.64% (as on 30 September 2009).